The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Tailoring therapy for patients with multiple myeloma to improve outcomes
Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the importance of tailoring treatment approaches for patients with multiple myeloma. Decisions should be made by taking into account factors such as the patient’s age, frailty and comorbidities, as well as the side effects of agents being used. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
